Fate Therapeutics (FATE) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. IVBIY

Go back to Fate Therapeutics (FATE) Reports In-Line Q4 EPS

Fate Therapeutics (FATE) PT Lowered to $8 at Jefferies

March 6, 2025 5:19 AM EST

Jefferies analyst Michael Yee lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $10.00) while maintaining a Buy rating.

The analyst comments "FATE has a new CEO and has presented initial promising data at ASH (1 remission so far) and has emphasized... More